ReviewJCO oncology practice2024
Breast Cancer Brain Metastasis: A Comprehensive Review.
Review in JCO oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Molecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Pooled it
- Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis.Cancer letters · 2026Review
- Saliency-Curated Deep Learning for Predicting Receptor Status in Breast Cancer Brain Metastases.Journal of clinical medicine · 2026Article
- Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort.Current oncology (Toronto, Ont.) · 2026Article
- Impact of High Lymph Node Burden on Brain Metastases in Patients Who Achieved Pathological Complete Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.Cancer research and treatment · 2026Article
- Spatial immune atlas of breast cancer brain metastasis reveals CD163Journal for immunotherapy of cancer · 2026Article
- Review
- Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer.Cancers · 2026Article
- Integrative Bioinformatic Analysis Identifies Key Genes Driving Breast Cancer Brain Metastasis.Diagnostics (Basel, Switzerland) · 2026Article
- Preliminary modeling of brain metastases in breast cancer: a neural network approach to risk factor analysis.BMC cancer · 2026Article
- A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer.ESMO open · 2026Article
- Differences in distant metastasis risk of breast cancer originating from various primary sites: a retrospective analysis based on the SEER database.Scientific reports · 2026Article
- Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy.Cancers · 2026Article
- Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.Journal of neuro-oncology · 2026Article
- Isocenter Optimization in WBRT: Concurrent Sparing of Lens and Lacrimal Gland via Anterior Penumbra Sharpening.Journal of applied clinical medical physics · 2026Article
- Breast Cancer Brain Metastases: Current Understanding and Future Directions.Current oncology reports · 2026Review
- Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer.Cancer innovation · 2026Review
- Breast cancer brain metastasis: from molecular insights to therapeutic innovation.Frontiers in immunology · 2026Review
- Trastuzumab deruxtecan in advanced breast cancer: a real-world study of efficacy and safety in Chinese cohort with HER2-positive and HER2-low expression.Frontiers in oncology · 2026Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The mechanisms underlying breast cancer brain metastasis (BCBM) development are complex, and its clinical presentation varies depending on the number, location, and size of brain metastases. Common symptoms include headache, neurologic deficits, and seizures. Diagnosis of BCBM typically relies on neuroimaging techniques, such as magnetic resonance imaging and computed tomography scans. Local therapies, such as surgery and stereotactic radiosurgery, can be used to control tumor growth and relieve symptoms. Whole-brain radiotherapy has been a mainstay of treatment for BCBM, but its use has been associated with cognitive decline. Systemic therapy with chemotherapy and targeted agents plays an increasingly important role in the management of BCBM. Novel agents, such as human epidermal growth factor receptor 2 (HER2)-targeted therapies and tyrosine kinase inhibitors, have shown promising results in improving survival for patients with HER2-positive and triple-negative BCBM. This comprehensive review synthesizes current knowledge, clinical insights, and evolving paradigms to provide a robust understanding and roadmap for optimizing the diagnosis and management of BCBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.